CY1117974T1 - ΥΠΟΚΑΤΕΣΤΗΜΕΝΑ ΠΑΡΑΓΩΓΑ 1,2,3,4-ΤΕΤΡΑΫΔΡΟΚΥΚΛΟΠΕΝΤΑ[b]ΙΝΔΟΛ-3-ΥΛ-ΟΞΙΚΟΥ ΟΞΕΟΣ ΧΡΗΣΙΜΑ ΣΤΗΝ ΑΓΩΓΗ ΑΥΤΟΑΝΟΣΩΝ ΚΑΙ ΦΛΕΓΜΟΝΩΔΩΝ ΔΙΑΤΑΡΑΧΩΝ - Google Patents
ΥΠΟΚΑΤΕΣΤΗΜΕΝΑ ΠΑΡΑΓΩΓΑ 1,2,3,4-ΤΕΤΡΑΫΔΡΟΚΥΚΛΟΠΕΝΤΑ[b]ΙΝΔΟΛ-3-ΥΛ-ΟΞΙΚΟΥ ΟΞΕΟΣ ΧΡΗΣΙΜΑ ΣΤΗΝ ΑΓΩΓΗ ΑΥΤΟΑΝΟΣΩΝ ΚΑΙ ΦΛΕΓΜΟΝΩΔΩΝ ΔΙΑΤΑΡΑΧΩΝInfo
- Publication number
- CY1117974T1 CY1117974T1 CY20161100860T CY161100860T CY1117974T1 CY 1117974 T1 CY1117974 T1 CY 1117974T1 CY 20161100860 T CY20161100860 T CY 20161100860T CY 161100860 T CY161100860 T CY 161100860T CY 1117974 T1 CY1117974 T1 CY 1117974T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- acetic acid
- acid derivatives
- substituted
- tetrahydrocycloides
- Prior art date
Links
- 230000001363 autoimmune Effects 0.000 title 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical class C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 title 1
- 201000009863 inflammatory diarrhea Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 abstract 2
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000002874 Acne Vulgaris Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 150000001242 acetic acid derivatives Chemical class 0.000 abstract 1
- 206010000496 acne Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/02—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
- C07C255/03—Mononitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται με ορισμένα υποκατεστημένα παράγωγα 1,2,3,4-τετραϋδροκυκλοπεντα[b]ινδο-3-υλ οξικού οξέος του Χημικού Τύπου (Ia) και τα φαρμακευτικώς αποδεκτά άλατα εξ' αυτών, τα οποία εκδηλώνουν χρήσιμες φαρμακολογικές ιδιότητες, για παράδειγμα, ως αγωνιστές του υποδοχέα S1P1. Επίσης παρέχονται μέσω της παρούσας εφεύρεσης και φαρμακευτικές συνθέσεις περιέχοντας ενώσεις της εφεύρεσης και μέθοδοι χρήσης των ενώσεων και συνθέσεων της εφεύρεσης στην αγωγή των συσχετιζόμενων με υποδοχέα S1P1 διαταραχών, για παράδειγμα, της ψωρίασης, της ρευματοειδούς αρθρίτιδας, της νόσου του Crohn, της απόρριψης μεταμοσχευμάτων, της πολλαπλής σκλήρυνσης, του συστημικού ερυθηματώδους λύκου, της ελκώδους κολίτιδας, του διαβήτη τύπου I, της ακμής, των μικροβιακών λοιμώξεων ή παθήσεων και των ιικών λοιμώξεων ή παθήσεων.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13567208P | 2008-07-23 | 2008-07-23 | |
US20937409P | 2009-03-06 | 2009-03-06 | |
PCT/US2009/004265 WO2010011316A1 (en) | 2008-07-23 | 2009-07-22 | SUBSTITUTED 1,2,3,4- TETRAHYDROCYCLOPENTA[b]INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1117974T1 true CY1117974T1 (el) | 2017-05-17 |
Family
ID=41134563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20161100860T CY1117974T1 (el) | 2008-07-23 | 2016-09-01 | ΥΠΟΚΑΤΕΣΤΗΜΕΝΑ ΠΑΡΑΓΩΓΑ 1,2,3,4-ΤΕΤΡΑΫΔΡΟΚΥΚΛΟΠΕΝΤΑ[b]ΙΝΔΟΛ-3-ΥΛ-ΟΞΙΚΟΥ ΟΞΕΟΣ ΧΡΗΣΙΜΑ ΣΤΗΝ ΑΓΩΓΗ ΑΥΤΟΑΝΟΣΩΝ ΚΑΙ ΦΛΕΓΜΟΝΩΔΩΝ ΔΙΑΤΑΡΑΧΩΝ |
Country Status (25)
Country | Link |
---|---|
US (7) | US8580841B2 (el) |
EP (1) | EP2326621B1 (el) |
JP (6) | JP5449351B2 (el) |
KR (8) | KR101728374B1 (el) |
CN (2) | CN102164891B (el) |
AU (1) | AU2009274569C1 (el) |
BR (1) | BRPI0916812B8 (el) |
CA (1) | CA2730500C (el) |
CY (1) | CY1117974T1 (el) |
DK (1) | DK2326621T3 (el) |
EA (1) | EA019252B1 (el) |
ES (1) | ES2589731T3 (el) |
HK (1) | HK1157333A1 (el) |
HR (1) | HRP20161133T1 (el) |
HU (1) | HUE030424T2 (el) |
IL (1) | IL210577A (el) |
LT (1) | LT2326621T (el) |
MX (2) | MX354134B (el) |
NZ (1) | NZ590474A (el) |
PL (1) | PL2326621T3 (el) |
PT (1) | PT2326621T (el) |
SI (1) | SI2326621T1 (el) |
SM (1) | SMT201600317B (el) |
WO (1) | WO2010011316A1 (el) |
ZA (1) | ZA201100571B (el) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2008338965A1 (en) * | 2007-12-18 | 2009-06-25 | Arena Pharmaceuticals, Inc. | Tetrahydrocyclopenta[b]indol-3-yl carboxylic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
JP2011510073A (ja) * | 2008-01-25 | 2011-03-31 | アリーナ ファーマシューティカルズ, インコーポレイテッド | S1P1アゴニストとして作用するジヒドロ−1H−ピロロ[1,2−a]インドール−1−イルカルボン酸誘導体 |
HUE030424T2 (en) * | 2008-07-23 | 2017-05-29 | Arena Pharm Inc | Substituted 1,2,3,4-tetrahydrocyclopenta [b] indol-3-ylacetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
BRPI0917923B1 (pt) | 2008-08-27 | 2022-04-05 | Arena Pharmaceuticals Inc | Derivado de ácido tricíclico substituído, sua composição, seu uso e processo para preparar a referida composição |
EP2493866A1 (en) | 2009-10-29 | 2012-09-05 | Bristol-Myers Squibb Company | Tricyclic heterocyclic compounds |
EP3378854B1 (en) | 2010-01-27 | 2022-12-21 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
JP2013521301A (ja) | 2010-03-03 | 2013-06-10 | アリーナ ファーマシューティカルズ, インコーポレイテッド | S1p1受容体修飾物質およびその結晶形の調製のためのプロセス |
US8987307B2 (en) | 2011-03-03 | 2015-03-24 | Hoffmann-La Roche Inc. | 3-amino-pyridines as GPBAR1 agonists |
CN104203935A (zh) | 2012-04-04 | 2014-12-10 | 霍夫曼-拉罗奇有限公司 | 作为gpbar1调节剂的1,2-哒嗪,1,6-哒嗪或嘧啶-苯甲酰胺衍生物 |
CN104837567B (zh) | 2012-12-06 | 2017-07-07 | 3M创新有限公司 | 液体涂布的基板上的离散液体涂层以及在形成层合物方面的用途 |
WO2014088936A1 (en) | 2012-12-06 | 2014-06-12 | 3M Innovative Properties Company | Precision coating of viscous liquids and use in forming laminates |
MX2021011472A (es) * | 2015-01-06 | 2022-08-17 | Arena Pharm Inc | Metodos de condiciones de tratamiento relacionadas con el receptor s1p1. |
KR102603199B1 (ko) | 2015-06-22 | 2023-11-16 | 아레나 파마슈티칼스, 인크. | S1p1 수용체-관련 장애에서의 사용을 위한 (r)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[b]인돌-3-일)아세트산 (화합물 1)의 결정성 l-아르기닌 염 |
WO2017004608A1 (en) | 2015-07-02 | 2017-01-05 | Exelixis, Inc. | Oxadiazole modulators of s1p methods of making and using |
WO2017004609A1 (en) | 2015-07-02 | 2017-01-05 | Exelixis, Inc. | Thiadiazole modulators of s1p and methods of making and using |
WO2018045149A1 (en) | 2016-09-02 | 2018-03-08 | Bristol-Myers Squibb Company | Substituted tricyclic heterocyclic compounds |
WO2018151873A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
CA3053416A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations |
US11278505B2 (en) * | 2017-04-24 | 2022-03-22 | University Of Massachusetts | Diagnosis and treatment of vitiligo |
JP7061570B2 (ja) | 2017-07-13 | 2022-04-28 | 東レ・ファインケミカル株式会社 | シクロアルキル(トリフルオロメチル)ベンゼンの製造方法 |
US11046646B2 (en) | 2017-08-09 | 2021-06-29 | Bristol-Myers Squibb Company | Alkylphenyl compounds |
WO2019032631A1 (en) | 2017-08-09 | 2019-02-14 | Bristol-Myers Squibb Company | OXIME ETHER COMPOUNDS |
MA52778A (fr) | 2018-06-06 | 2021-04-21 | Arena Pharm Inc | Méthodes de traitement de troubles associés au récepteur s1p1 |
EP3847158A1 (en) | 2018-09-06 | 2021-07-14 | Arena Pharmaceuticals, Inc. | Compounds useful in the treatment of autoimmune and inflammatory disorders |
JP7265620B2 (ja) * | 2018-10-03 | 2023-04-26 | アリーナ ファーマシューティカルズ, インコーポレイテッド | 強皮症の治療のための方法 |
KR20210098487A (ko) | 2018-11-30 | 2021-08-10 | 아레나 파마슈티칼스, 인크. | S1p1 수용체와 관련된 병태의 치료 방법 |
CN113185446A (zh) * | 2018-12-06 | 2021-07-30 | 上海济煜医药科技有限公司 | 作为免疫调节的芳环衍生物及其制备方法和应用 |
AU2020206700A1 (en) | 2019-01-08 | 2021-07-15 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P |
MX2022003982A (es) * | 2019-10-01 | 2022-07-12 | Arena Pharm Inc | Metodos de tratamiento de enfermedades relacionadas con el receptor s1p1. |
IL292529A (en) | 2019-10-31 | 2022-06-01 | Idorsia Pharmaceuticals Ltd | Combination of cxcr7 antagonist with s1p1 receptor modulator |
AU2020389144A1 (en) * | 2019-11-20 | 2022-06-09 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
JPWO2021157682A1 (el) | 2020-02-06 | 2021-08-12 | ||
US20230357148A1 (en) * | 2020-07-03 | 2023-11-09 | Shanghai Medicilon Inc. | Indole derivative and application thereof |
JP2023548474A (ja) * | 2020-11-09 | 2023-11-17 | アリーナ ファーマシューティカルズ, インコーポレイテッド | S1p1受容体に関連する状態を処置する方法 |
CN112812052B (zh) * | 2021-02-02 | 2023-12-01 | 成都阿奇生物医药科技有限公司 | 一种治疗溃疡性结肠炎的化合物及其制备方法和用途 |
WO2023109931A1 (zh) * | 2021-12-17 | 2023-06-22 | 上海济煜医药科技有限公司 | 一种芳环衍生物的晶型及其制备方法和应用 |
EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
WO2023135506A1 (en) | 2022-01-13 | 2023-07-20 | Arena Pharmaceuticals, Inc. | Etrasimod for use in treating s1p1 receptor-associated disorders in combination with hormone treatment |
WO2023170585A1 (en) * | 2022-03-09 | 2023-09-14 | Arena Pharmaceuticals, Inc. | Novel s1p1 receptor agonist, crystalline salts, processes for preparing, and uses related thereto |
WO2023214312A1 (en) | 2022-05-06 | 2023-11-09 | Arena Pharmaceuticals, Inc. | Methods of treating atopic dermatitis with etrasimod |
CN116854622A (zh) * | 2023-07-10 | 2023-10-10 | 青岛科技大学 | 一种多取代的2,4-二氢环戊二烯并[b]吲哚类化合物的合成方法 |
Family Cites Families (151)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL293572A (el) | 1962-06-07 | |||
US3843681A (en) * | 1971-06-01 | 1974-10-22 | American Home Prod | 1-carboxamido pyrano(thiopyrano)(3,4-6)indole derivatives |
DE2226703A1 (de) | 1972-05-25 | 1973-12-13 | Schering Ag | Neue tetrahydrocarbazolderivate und verfahren zu ihrer herstellung |
US4057559A (en) * | 1973-10-01 | 1977-11-08 | American Home Products Corporation | Carbazole acetic acid derivatives |
US4810699A (en) * | 1987-02-20 | 1989-03-07 | American Home Products Corporation | Substituted 1,3,4,9-tetrahydropyrano[3,4,-b]indole-1-acetic acids, pharmaceutical compositions containing them, and methods for treating inflammatory conditions and for analgesic purposes using them |
US4782076A (en) * | 1988-03-01 | 1988-11-01 | American Home Products Corporation | Substituted 2,3,4,9-tetrahydro-1H-carbazole-1-acetic acid derivatives, composition and use |
PT95692A (pt) * | 1989-10-27 | 1991-09-13 | American Home Prod | Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase |
US5221678A (en) * | 1990-07-26 | 1993-06-22 | Merck Frosst Canada, Inc. | (quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes |
US5998499A (en) | 1994-03-25 | 1999-12-07 | Dentsply G.M.B.H. | Liquid crystalline (meth)acrylate compounds, composition and method |
US5776967A (en) * | 1996-07-26 | 1998-07-07 | American Home Products Corporation | Pyranoindole inhibitors of COX--2 |
US5830911A (en) * | 1996-08-14 | 1998-11-03 | American Home Products Corporation | Pyranoindole and tetrahydrocarbazole inhibitors of COX-2 |
US6861448B2 (en) * | 1998-01-14 | 2005-03-01 | Virtual Drug Development, Inc. | NAD synthetase inhibitors and uses thereof |
JP4038266B2 (ja) * | 1998-02-17 | 2008-01-23 | オイレス工業株式会社 | 粘性せん断型ダンパー |
JP4598278B2 (ja) | 1999-04-28 | 2010-12-15 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Ppar受容体リガンドとしてのジアリール酸誘導体 |
US6410583B1 (en) * | 2000-07-25 | 2002-06-25 | Merck Frosst Canada & Co. | Cyclopentanoindoles, compositions containing such compounds and methods of treatment |
WO2002039987A2 (en) | 2000-11-14 | 2002-05-23 | Neurosearch A/S | Use of malaria parasite anion channel blockers for treating malaria |
WO2002064616A2 (en) | 2001-01-30 | 2002-08-22 | University Of Virgina Patent Foundation | Agonists and antagonists of sphingosine-1-phosphate receptors |
KR100876047B1 (ko) * | 2001-03-29 | 2008-12-26 | 오사까 가스 가부시키가이샤 | 광활성 화합물 및 감광성 수지 조성물 |
DE60230262D1 (de) | 2001-05-10 | 2009-01-22 | Ono Pharmaceutical Co | Carbonsäurederivate und diese als wirkstoff enthaltende arzneimittel |
DE60223699T2 (de) * | 2001-09-27 | 2008-10-30 | Kyorin Pharmaceutical Co., Ltd. | Diarylsulfidderivat, dessen additionssalz und immunsuppressivum |
AU2003216054B2 (en) | 2002-01-18 | 2007-01-04 | Merck & Co., Inc. | Selective S1P1/Edg1 receptor agonists |
WO2003062252A1 (en) | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | Edg receptor agonists |
US20050239899A1 (en) * | 2002-01-18 | 2005-10-27 | Wolfgang Fecke | Beta-secretase inhibitors |
US7309721B2 (en) | 2002-03-01 | 2007-12-18 | Merck + Co., Inc. | Aminoalkylphosphonates and related compounds as Edg receptor agonists |
WO2003074008A2 (en) | 2002-03-01 | 2003-09-12 | Merck & Co., Inc. | Aminoalkylphosphonates and related compounds as edg receptor agonists |
JP2005533058A (ja) | 2002-06-17 | 2005-11-04 | メルク エンド カムパニー インコーポレーテッド | Edg受容体アゴニストとしての1−((5−アリール−1,2,4−オキサジアゾール−3−イル)ベンジル)アゼチジン−3−カルボキシラートおよび1−((5−アリール−1,2,4−オキサジアゾール−3−イル)ベンジル)ピロリジン−3−カルボキシラート |
AU2003252478A1 (en) * | 2002-07-10 | 2004-02-02 | Ono Pharmaceutical Co., Ltd. | Ccr4 antagonist and medicinal use thereof |
EP1546110A4 (en) | 2002-07-30 | 2008-03-26 | Univ Virginia | ACTIVE COMPOUNDS IN THE SIGNALING OF SPHINGOSINE 1-PHOSPHATE |
AU2003277576A1 (en) * | 2002-11-08 | 2004-06-07 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
JP4516430B2 (ja) | 2002-12-20 | 2010-08-04 | メルク・シャープ・エンド・ドーム・コーポレイション | 1−(アミノ)インダン並びに(1,2−ジヒドロ−3−アミノ)−ベンゾフラン、ベンゾチオフェン及びインドール |
EP1594508B1 (en) | 2003-02-11 | 2012-08-08 | Irm Llc | Novel bicyclic compounds and compositions |
KR101005171B1 (ko) * | 2003-02-18 | 2011-01-04 | 교린 세이야꾸 가부시키 가이샤 | 아미노포스폰산 유도체와 그 부가염 및 s1p 수용체조절제 |
AU2004234067B2 (en) * | 2003-04-30 | 2008-02-28 | Novartis Ag | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators |
WO2004099192A2 (en) * | 2003-04-30 | 2004-11-18 | The Institutes Of Pharmaceutical Discovery, Llc | Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b |
BRPI0410025A (pt) | 2003-04-30 | 2006-04-25 | Novartis Ag | derivados de amino-propanol como modulador do receptor de esfingosina-1-fosfato |
WO2004103279A2 (en) | 2003-05-15 | 2004-12-02 | Merck & Co., Inc. | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists |
WO2004104205A2 (en) | 2003-05-16 | 2004-12-02 | Merck & Co., Inc. | Enzymatic preparation of chiral indole esters |
BRPI0410746A (pt) | 2003-05-19 | 2006-06-27 | Irm Llc | compostos e composições imunossupressoras |
US7060697B2 (en) * | 2003-05-19 | 2006-06-13 | Irm Llc | Immunosuppressant compounds and compositions |
MY150088A (en) * | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
MXPA05012461A (es) | 2003-05-19 | 2006-02-22 | Irm Llc | Compuestos y composiciones inmunosupresores. |
GB0313612D0 (en) * | 2003-06-12 | 2003-07-16 | Novartis Ag | Organic compounds |
EP1661879A4 (en) * | 2003-08-04 | 2006-11-29 | Ono Pharmaceutical Co | A DIPHENYL ETHER COMPOUND, PROCESS FOR THE PRODUCTION AND USE THEREOF |
CN102175786B (zh) | 2003-08-28 | 2013-07-17 | 诺瓦提斯公司 | 氨基丙醇衍生物 |
CN101407471A (zh) * | 2003-08-29 | 2009-04-15 | 小野药品工业株式会社 | 能够结合s1p受体的化合物及其药物用途 |
WO2005020882A2 (ja) | 2003-08-29 | 2005-03-10 | Ono Pharmaceutical Co | S1p受容体結合能を有する化合物およびその医薬用途 |
US7732442B2 (en) * | 2003-09-05 | 2010-06-08 | Ono Pharmaceutical Co., Ltd. | Chemokine receptor antagonist and medical use thereof |
US20070043014A1 (en) * | 2003-10-01 | 2007-02-22 | Merck & Co., Inc. | 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists |
WO2005041899A2 (en) | 2003-11-03 | 2005-05-12 | University Of Virginia Patent Foundation | Orally available sphingosine 1-phosphate receptor agonists and antagonists |
JPWO2005044780A1 (ja) | 2003-11-10 | 2007-05-17 | 杏林製薬株式会社 | アミノカルボン酸誘導体とその付加塩及びs1p受容体調節剤 |
WO2005058848A1 (en) | 2003-12-17 | 2005-06-30 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists |
GB0329498D0 (en) | 2003-12-19 | 2004-01-28 | Novartis Ag | Organic compounds |
US7875745B2 (en) * | 2003-12-19 | 2011-01-25 | Ono Pharmaceutical Co., Ltd. | Compounds having lysophosphatidic acid receptor antagonism and uses thereof |
GB0401332D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
AU2005215320B2 (en) * | 2004-02-24 | 2008-04-17 | Sankyo Company, Limited | Amino alcohol compound |
TW200538433A (en) | 2004-02-24 | 2005-12-01 | Irm Llc | Immunosuppressant compounds and compositiions |
WO2005082841A1 (en) | 2004-02-24 | 2005-09-09 | Irm Llc | Immunosuppressant compounds and compositions |
EP1726585A4 (en) * | 2004-03-05 | 2009-07-15 | Banyu Pharma Co Ltd | HETEROCYCLIC DERIVATIVE WITH FIVE ELEMENTS SUBSTITUTED BY A DIARYLE |
GB0405289D0 (en) | 2004-03-09 | 2004-04-21 | Novartis Ag | Organic compounds |
SI1737820T1 (sl) | 2004-04-02 | 2008-04-30 | Merck & Co Inc | Postopek asimetricne hidrogenacije, uporaben pri pripravi cikloalkanoidolnih derivatov |
WO2005123677A1 (en) | 2004-06-16 | 2005-12-29 | Actelion Pharmaceuticals Ltd | 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents |
JP5315611B2 (ja) | 2004-06-23 | 2013-10-16 | 小野薬品工業株式会社 | S1p受容体結合能を有する化合物およびその用途 |
EP1772145B1 (en) | 2004-07-16 | 2011-03-23 | Kyorin Pharmaceutical Co., Ltd. | Method of effectively using medicine and method concerning prevention of side effect |
JP2007284350A (ja) * | 2004-07-27 | 2007-11-01 | Takeda Chem Ind Ltd | 糖尿病治療剤 |
WO2006010379A1 (en) | 2004-07-29 | 2006-02-02 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives as immunosuppressive agents |
TW200611687A (en) * | 2004-07-29 | 2006-04-16 | Sankyo Co | Pharmaceutical compositions used for immunosuppressant |
CN1993333B (zh) * | 2004-08-04 | 2012-08-01 | 大正制药株式会社 | 三唑衍生物 |
US20060223866A1 (en) * | 2004-08-13 | 2006-10-05 | Praecis Pharmaceuticals, Inc. | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity |
US7241812B2 (en) | 2004-08-13 | 2007-07-10 | Praecis Pharmaceuticals, Inc. | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity |
JP2008514611A (ja) * | 2004-09-23 | 2008-05-08 | ワイス | C型肝炎ウイルスによる感染を処置するためのカルバゾールおよびシクロペンタインドールの誘導体 |
BRPI0515992A (pt) * | 2004-10-12 | 2008-08-19 | Forbes Medi Tech Res Inc | compostos e métodos para o tratamento de resistência à insulina e cardiomiopatia |
PL1650186T3 (pl) | 2004-10-22 | 2008-11-28 | Bioprojet Soc Civ | Nowe pochodne kwasów dikarboksylowych |
JP2008517915A (ja) | 2004-10-22 | 2008-05-29 | メルク エンド カムパニー インコーポレーテッド | S1p受容体アゴニストとしての2−(アリール)アザシクリルメチルカルボキシレート、スルホネート、ホスホネート、ホスフィネート及びヘテロ環 |
AU2005307718A1 (en) * | 2004-11-18 | 2006-05-26 | The Institutes For Pharmaceutical Discovery, Llc | Heterocycle substituted carboxylic acids for the treatment of diabetes |
EP1829863A4 (en) * | 2004-11-26 | 2009-04-22 | Takeda Pharmaceutical | ARYLALCANOIC ACID DERIVATIVE |
EP1827606A2 (en) | 2004-12-06 | 2007-09-05 | University Of Virginia Patent Foundation | Aryl amide sphingosine 1-phosphate analogs |
US7906549B2 (en) | 2004-12-13 | 2011-03-15 | Ono Pharmaceutical Co., Ltd. | Aminocarboxylic acid derivative and medicinal use thereof |
DE112005003337T5 (de) | 2005-01-25 | 2008-02-21 | Merck Patent Gmbh | Mesogene Verbindungen, Flüssigkristallmedium und Flüssigkristallanzeige |
JP2008530135A (ja) | 2005-02-14 | 2008-08-07 | ユニバーシティ オブ バージニア パテント ファンデーション | アミノ基およびフェニル基で置換されたシクロアルカンならびに5員の複素環を含むスフィンゴシン=1−リン酸アゴニスト |
PT1863787E (pt) | 2005-03-23 | 2011-07-29 | Actelion Pharmaceuticals Ltd | Derivados de benzo(c)tiofenos hidrogenados como imunomoduladores |
BRPI0609665A2 (pt) | 2005-03-23 | 2010-04-20 | Actelion Pharmaceuticals Ltd | composto, composição farmacêutica, e, uso de um composto |
MX2007011672A (es) | 2005-03-23 | 2007-11-15 | Actelion Pharmaceuticals Ltd | Nuevos derivados de tiofeno como agonistas del receptor de esfingosina-1-fosfato-1. |
US20080306124A1 (en) | 2005-06-08 | 2008-12-11 | Rainer Albert | Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands |
RU2008101805A (ru) | 2005-06-24 | 2009-07-27 | Актелион Фармасьютиклз Лтд (Ch) | Новые производные тиофена |
TWI418350B (zh) * | 2005-06-24 | 2013-12-11 | Sankyo Co | 含有ppar調節劑之醫藥組成物的用途 |
US20070060573A1 (en) * | 2005-08-10 | 2007-03-15 | Lars Wortmann | Acyltryptophanols |
BRPI0615133A2 (pt) | 2005-08-23 | 2011-05-03 | Irm Llc | compostos imunossupressores, composições farmacêuticas contendo os mesmos assim como referido uso |
WO2007037196A1 (ja) | 2005-09-29 | 2007-04-05 | Yamamoto Chemicals, Inc. | インドリン系化合物及びその製造方法 |
AR057894A1 (es) | 2005-11-23 | 2007-12-26 | Actelion Pharmaceuticals Ltd | Derivados de tiofeno |
EP1965807A4 (en) | 2005-11-23 | 2010-10-27 | Epix Delaware Inc | S1P RECEPTOR MODULATING COMPOUNDS AND THEIR USE |
TWI404706B (zh) | 2006-01-11 | 2013-08-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
TW200736234A (en) | 2006-01-17 | 2007-10-01 | Astrazeneca Ab | Chemical compounds |
AU2007209051A1 (en) | 2006-01-24 | 2007-08-02 | Actelion Pharmaceuticals Ltd | Novel pyridine derivatives |
GB0601744D0 (en) | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
TWI389683B (zh) * | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
TW200806611A (en) | 2006-02-09 | 2008-02-01 | Daiichi Seiyaku Co | Novel amidopropionic acid derivatives and medicine containing the same |
JP2009526073A (ja) | 2006-02-09 | 2009-07-16 | ユニバーシティ オブ バージニア パテント ファンデーション | 二環式スフィンゴシン−1−リン酸受容体アナログ |
US20070191371A1 (en) * | 2006-02-14 | 2007-08-16 | Kalypsys, Inc. | Heterocyclic modulators of ppar |
CN101460458A (zh) * | 2006-02-15 | 2009-06-17 | 阿勒根公司 | 具有1-磷酸-鞘氨醇(s1p)受体拮抗剂生物活性的带芳基或者杂芳基基团的吲哚-3-羧酸的酰胺、酯、硫代酰胺和硫羟酸酯化合物 |
EP1984334B1 (en) | 2006-02-15 | 2014-04-09 | Allergan, Inc. | Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (s1p) receptor antagonist biological activity |
EP1991535A1 (en) | 2006-02-21 | 2008-11-19 | University Of Virginia Patent Foundation | Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as sip receptor agonists |
US7649098B2 (en) | 2006-02-24 | 2010-01-19 | Lexicon Pharmaceuticals, Inc. | Imidazole-based compounds, compositions comprising them and methods of their use |
MX2008011615A (es) * | 2006-03-14 | 2008-09-22 | Amgen Inc | Derivados de acidos carboxilicos biciclicos utiles para tratar trastornos metabolicos. |
AU2007227274A1 (en) | 2006-03-21 | 2007-09-27 | Epix Delaware, Inc. | S1P receptor modulating compounds |
JP2007262009A (ja) | 2006-03-29 | 2007-10-11 | Dai Ichi Seiyaku Co Ltd | ヘテロアリール低級カルボン酸誘導体 |
CA2648303C (en) * | 2006-04-03 | 2014-07-15 | Astellas Pharma Inc. | 5-[monocyclic(hetero)arylsubstituted-1,2,4-oxadliazol-3-yl]-(fused heteroaryl substituted) compounds and their use as s1p1 agonists |
GB0607389D0 (en) | 2006-04-12 | 2006-05-24 | Novartis Ag | Organic compounds |
US20090324581A1 (en) | 2006-05-09 | 2009-12-31 | Daiichi Sankyo Company Limited | Heteroarylamide lower carboxylic acid derivative |
EA200802058A1 (ru) | 2006-05-09 | 2009-06-30 | Пфайзер Продактс Инк. | Производные циклоалкиламинокислот и их фармацевтические композиции |
WO2007129473A1 (ja) | 2006-05-09 | 2007-11-15 | Daiichi Sankyo Company, Limited | 二環性アリール誘導体 |
US20080070866A1 (en) | 2006-08-01 | 2008-03-20 | Praecis Pharmaceuticals Incorporated | Chemical compounds |
AR062156A1 (es) | 2006-08-01 | 2008-10-22 | Praecis Pharm Inc | Compuestos agonistas y selectivos del receptor s1p-1 |
WO2008019090A2 (en) | 2006-08-04 | 2008-02-14 | Praecis Pharmaceuticals Incorporated | Agonists of the sphingosine-1-phosphate receptor |
DK2058317T3 (da) * | 2006-08-08 | 2014-01-06 | Kyorin Seiyaku Kk | Aminophosphorsyreesterderivat og S1P receptormodulator indeholdende samme som aktiv ingrediens |
EP2054377A1 (en) | 2006-08-24 | 2009-05-06 | Praecis Pharmaceuticals Incorporated | Chemical compounds |
JP2009269819A (ja) | 2006-08-25 | 2009-11-19 | Asahi Kasei Pharma Kk | アミン化合物 |
AU2007292993B2 (en) | 2006-09-07 | 2013-01-24 | Idorsia Pharmaceuticals Ltd | Pyridin-4-yl derivatives as immunomodulating agents |
CA2662852A1 (en) | 2006-09-07 | 2008-03-13 | Allergan, Inc. | Heteroaromatic compounds having sphingosine-1-phosphate (s1p) receptor agonist and/or antagonist biological activity |
TWI408139B (zh) | 2006-09-07 | 2013-09-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
EP2081888A1 (en) | 2006-09-08 | 2009-07-29 | Novartis AG | N-biaryl (hetero) arylsulphonamide derivatives useful in the treatment of diseases mediated by lymphocytes interactions |
AU2007298593A1 (en) | 2006-09-21 | 2008-03-27 | Actelion Pharmaceuticals Ltd | Phenyl derivatives and their use as immunomodulators |
AU2007334436A1 (en) | 2006-12-15 | 2008-06-26 | Abbott Laboratories | Novel oxadiazole compounds |
GB0625648D0 (en) | 2006-12-21 | 2007-01-31 | Glaxo Group Ltd | Compounds |
JO2701B1 (en) | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
MX2009006751A (es) | 2006-12-21 | 2009-06-30 | Abbott Lab | Compuestos agonistas y antagonistas del receptor de esfingosina-1-fosfato. |
CN101668741A (zh) | 2007-01-11 | 2010-03-10 | 阿勒根公司 | 具有鞘氨醇-1-磷酸(s1p)受体拮抗剂生物学活性的6-取代吲哚-3-羧酸酰胺化合物 |
WO2008091967A1 (en) | 2007-01-26 | 2008-07-31 | Smithkline Beecham Corporation | Chemical compounds |
WO2008097819A2 (en) | 2007-02-05 | 2008-08-14 | Smithkline Beecham Corporation | Chemical compounds |
MX2009009597A (es) | 2007-03-16 | 2009-09-16 | Actelion Pharmaceuticals Ltd | Derivados de amino-piridina como agonistas del receptor s1p1/edg1. |
EP2364976B1 (en) | 2007-03-21 | 2014-10-08 | EPIX Pharmaceuticals, Inc. | S1P receptor modulating compounds and use thereof |
MX2009011155A (es) | 2007-04-19 | 2009-10-30 | Glaxo Group Ltd | Derivados de indazol oxadiazol sustituidos para su uso como agonistas de esfingosina-1-fosfato (s1p). |
EP2014653A1 (en) | 2007-06-15 | 2009-01-14 | Bioprojet | Novel dicarboxylic acid derivatives as S1P1 receptor agonists |
US20090069288A1 (en) | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
WO2009019506A1 (en) | 2007-08-03 | 2009-02-12 | Astrazeneca Ab | Heterocyclyc sulfonamides having edg-1 antagonistic activity |
US8399448B2 (en) | 2007-08-08 | 2013-03-19 | Merck Serono Sa | 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (S1P) receptor for the treatment of multiple sclerosis |
TW200930368A (en) | 2007-11-15 | 2009-07-16 | Astrazeneca Ab | Bis-(sulfonylamino) derivatives in therapy |
AU2008338965A1 (en) * | 2007-12-18 | 2009-06-25 | Arena Pharmaceuticals, Inc. | Tetrahydrocyclopenta[b]indol-3-yl carboxylic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
JP2011510073A (ja) * | 2008-01-25 | 2011-03-31 | アリーナ ファーマシューティカルズ, インコーポレイテッド | S1P1アゴニストとして作用するジヒドロ−1H−ピロロ[1,2−a]インドール−1−イルカルボン酸誘導体 |
AR070398A1 (es) | 2008-02-22 | 2010-03-31 | Gruenenthal Chemie | Derivados sustituidos de indol |
HUE025984T2 (hu) | 2008-05-14 | 2016-05-30 | Scripps Research Inst | Szfingozin foszfát receptor új modulátorai |
WO2009151621A1 (en) | 2008-06-13 | 2009-12-17 | Arena Pharmaceuticals, Inc. | Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists |
WO2009151626A1 (en) | 2008-06-13 | 2009-12-17 | Arena Pharmaceuticals, Inc. | Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists |
HUE030424T2 (en) | 2008-07-23 | 2017-05-29 | Arena Pharm Inc | Substituted 1,2,3,4-tetrahydrocyclopenta [b] indol-3-ylacetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
BRPI0917923B1 (pt) | 2008-08-27 | 2022-04-05 | Arena Pharmaceuticals Inc | Derivado de ácido tricíclico substituído, sua composição, seu uso e processo para preparar a referida composição |
BRPI1008060A2 (pt) | 2009-02-10 | 2015-08-25 | Abbott Lab | Agonistas e antagonistas do receptor s1p5, e métodos de uso do mesmo. |
WO2011005290A1 (en) | 2009-06-23 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Disubstituted oxadiazole derivatives useful in the treatment of autoimmune and inflammatory disorders |
WO2011005295A1 (en) | 2009-06-24 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto |
EP2493866A1 (en) | 2009-10-29 | 2012-09-05 | Bristol-Myers Squibb Company | Tricyclic heterocyclic compounds |
EP3378854B1 (en) | 2010-01-27 | 2022-12-21 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
JP2013521301A (ja) | 2010-03-03 | 2013-06-10 | アリーナ ファーマシューティカルズ, インコーポレイテッド | S1p1受容体修飾物質およびその結晶形の調製のためのプロセス |
JP2013533286A (ja) | 2010-07-30 | 2013-08-22 | セントルイス ユニバーシティ | 疼痛を治療する方法 |
-
2009
- 2009-07-22 HU HUE09788983A patent/HUE030424T2/en unknown
- 2009-07-22 KR KR1020117004027A patent/KR101728374B1/ko active IP Right Grant
- 2009-07-22 KR KR1020227019424A patent/KR20220084423A/ko not_active Application Discontinuation
- 2009-07-22 MX MX2013012323A patent/MX354134B/es unknown
- 2009-07-22 NZ NZ59047409A patent/NZ590474A/xx unknown
- 2009-07-22 ES ES09788983.6T patent/ES2589731T3/es active Active
- 2009-07-22 EP EP09788983.6A patent/EP2326621B1/en active Active
- 2009-07-22 KR KR1020207028189A patent/KR20200117058A/ko active Application Filing
- 2009-07-22 EA EA201170251A patent/EA019252B1/ru unknown
- 2009-07-22 CA CA2730500A patent/CA2730500C/en active Active
- 2009-07-22 KR KR1020197034224A patent/KR20190132565A/ko not_active Application Discontinuation
- 2009-07-22 KR KR1020177009881A patent/KR20170044760A/ko active Application Filing
- 2009-07-22 CN CN200980137275.7A patent/CN102164891B/zh active Active
- 2009-07-22 LT LTEP09788983.6T patent/LT2326621T/lt unknown
- 2009-07-22 BR BRPI0916812A patent/BRPI0916812B8/pt active IP Right Grant
- 2009-07-22 KR KR1020197000397A patent/KR20190004843A/ko active Application Filing
- 2009-07-22 PL PL09788983.6T patent/PL2326621T3/pl unknown
- 2009-07-22 MX MX2011000879A patent/MX2011000879A/es active IP Right Grant
- 2009-07-22 SI SI200931514A patent/SI2326621T1/sl unknown
- 2009-07-22 KR KR1020187005352A patent/KR20180023049A/ko active Application Filing
- 2009-07-22 CN CN201410403616.3A patent/CN104311472B9/zh active Active
- 2009-07-22 DK DK09788983.6T patent/DK2326621T3/en active
- 2009-07-22 PT PT97889836T patent/PT2326621T/pt unknown
- 2009-07-22 US US13/055,333 patent/US8580841B2/en active Active
- 2009-07-22 JP JP2011520040A patent/JP5449351B2/ja active Active
- 2009-07-22 KR KR1020217024737A patent/KR20210099206A/ko not_active Application Discontinuation
- 2009-07-22 AU AU2009274569A patent/AU2009274569C1/en active Active
- 2009-07-22 WO PCT/US2009/004265 patent/WO2010011316A1/en active Application Filing
-
2011
- 2011-01-11 IL IL210577A patent/IL210577A/en active IP Right Grant
- 2011-01-21 ZA ZA2011/00571A patent/ZA201100571B/en unknown
- 2011-10-27 HK HK11111623.9A patent/HK1157333A1/zh unknown
-
2013
- 2013-10-08 US US14/048,768 patent/US9126932B2/en active Active
- 2013-12-24 JP JP2013265453A patent/JP2014144948A/ja not_active Withdrawn
-
2015
- 2015-08-04 US US14/817,455 patent/US9522133B2/en active Active
- 2015-09-25 JP JP2015187684A patent/JP2016029067A/ja not_active Withdrawn
-
2016
- 2016-09-01 CY CY20161100860T patent/CY1117974T1/el unknown
- 2016-09-05 HR HRP20161133TT patent/HRP20161133T1/hr unknown
- 2016-09-14 SM SM201600317T patent/SMT201600317B/it unknown
- 2016-11-09 US US15/347,130 patent/US20170217885A1/en not_active Abandoned
-
2018
- 2018-02-09 JP JP2018021712A patent/JP2018090603A/ja not_active Withdrawn
- 2018-07-17 US US16/037,309 patent/US20190135752A1/en not_active Abandoned
-
2019
- 2019-08-02 JP JP2019142798A patent/JP2019206570A/ja not_active Withdrawn
-
2020
- 2020-06-08 US US16/895,671 patent/US20200407316A1/en not_active Abandoned
-
2021
- 2021-04-14 JP JP2021068167A patent/JP2021107425A/ja active Pending
-
2022
- 2022-08-11 US US17/885,683 patent/US20230257349A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1117974T1 (el) | ΥΠΟΚΑΤΕΣΤΗΜΕΝΑ ΠΑΡΑΓΩΓΑ 1,2,3,4-ΤΕΤΡΑΫΔΡΟΚΥΚΛΟΠΕΝΤΑ[b]ΙΝΔΟΛ-3-ΥΛ-ΟΞΙΚΟΥ ΟΞΕΟΣ ΧΡΗΣΙΜΑ ΣΤΗΝ ΑΓΩΓΗ ΑΥΤΟΑΝΟΣΩΝ ΚΑΙ ΦΛΕΓΜΟΝΩΔΩΝ ΔΙΑΤΑΡΑΧΩΝ | |
CY1117830T1 (el) | Υποκατεστημενα παραγωγα τρικυκλικων οξεων ως αγωνιστες του υποδοχεα s1p1 χρησιμα στην αγωγη αυτοανοσων και φλεγμονοδων διαταραχων | |
ATE531711T1 (de) | Für die behandlung von autoimmunerkrankungen und entzündlichen erkrankungen geeignete tetrahydrocyclopentaäbüindol-3- ylcarbonsäurederivate | |
MA37405A1 (fr) | Composés hétérocyclyle | |
BR112015028452A2 (pt) | agonistas do receptor somastatina subtipo 4 (sstr4) | |
PH12014502524B1 (en) | Carboxylic acid compounds | |
EA201170705A1 (ru) | Арилметилбензохиназолиноны в качестве позитивных аллостерических модуляторов рецептора м1 | |
PA8825301A1 (es) | Derivados de acido ciclopentanocarboxilico condensados sustituidos con acilamino y su uso como productos farmaceuticos | |
EA201291220A1 (ru) | Производные аминопиримидина в качестве модуляторов lrrk2 | |
TN2009000180A1 (en) | NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF | |
EA201071329A1 (ru) | Диамидные производные адамантана и их применение | |
BR112012018384A2 (pt) | composição farmacêutica sólida com intensificadores e métodos de preparação da mesma. | |
BRPI1013821A8 (pt) | piridinas substituídas como antagonistas de ccr3. | |
EA201270216A1 (ru) | Фармацевтический состав | |
WO2011005295A8 (en) | Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto | |
EA023861B3 (ru) | Производные пирролидин карбоновой кислоты как агонисты сопряженного с g-белком рецептора 43 (gpr43), фармацевтическая композиция и методы их использования при лечении метаболических нарушений | |
GEP20166483B (en) | Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament | |
MX2009000169A (es) | Derivados de purinona como agonistas de hm74a. | |
CY1120530T1 (el) | Απο του στοματος χορηγησιμη φαρμακευτικη συνθεση | |
CY1113759T1 (el) | Ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2 | |
ECSP099063A (es) | Derivados de purina como agonistas de a2a | |
MA34094B1 (fr) | Dérivés de 3-(hétéroarylamino)-1,2,3,4-tétrahydro-9h-carbazole et leur utilisation comme modulateurs du récepteur de la prostaglandine d2 | |
BR112015007503A2 (pt) | derivados de oxazolina terapeuticamente ativos | |
FR2981933B1 (fr) | Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique | |
GT200500214A (es) | Amidas del acido 5 y 6-aminoalquil indol-2-carboxilico 3-sustituidas y análogos relacionados como inhibidores de la caseína cinasa epsilon |